- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00220415
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Male and female patients between 16 and 70 years of age who are diagnosed with epilepsy with partial seizures and are taking up to 3 medications for this medical condition will take part in this research study at approximately 80 different locations in Australia and Europe.
The purpose of this study is to evaluate the effectiveness, safety and tolerability of consistent dosages of study drug (lacosamide) taken orally twice a day for about 4 months.
Each patient who qualifies and chooses to participate in the study will receive placebo (inactive drug) or gradually increasing doses of lacosamide (SPM 927) up to the target dose of 200mg/day or 400mg/day. The target dose or placebo will be maintained for 12 weeks.
The study clinic visits will include a medical history and physical exam, ECG, blood and urine sample collection, and completion of a seizure diary.
Patients who complete the study may enroll in an extension trial and receive active study drug.
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Monheim, Germany
- Schwarz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- partial seizures with or without secondary generalization
Exclusion Criteria:
- subjects received SPM 927 in a previous trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Sake JK, Hebert D, Isojarvi J, Doty P, De Backer M, Davies K, Eggert-Formella A, Zackheim J. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010 Dec;24(12):1055-68. doi: 10.2165/11587550-000000000-00000.
- Borghs S, de la Loge C, Cramer JA. Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy Behav. 2012 Mar;23(3):230-4. doi: 10.1016/j.yebeh.2011.12.023. Epub 2012 Feb 15.
- Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav. 2015 Nov;52(Pt A):119-27. doi: 10.1016/j.yebeh.2015.09.006. Epub 2015 Sep 27.
- Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009 Mar;50(3):443-53. doi: 10.1111/j.1528-1167.2008.01951.x. Epub 2009 Jan 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP0755
- 2004-000290-58 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Partial Seizures With or Without Secondary Generalization
-
University Hospital Schleswig-HolsteinCompletedEpilepsy With Partial Onset Seizures With or Without Secondary GeneralizationGermany
-
UCB Biopharma SRLCompletedEpilepsy | Partial Seizures With or Without Secondary GeneralizationChina, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand
-
UCB Biopharma S.P.R.L.CompletedEpilepsy | Partial Seizures With or Without Secondary GeneralizationJapan
-
UCB Biopharma SRLEnrolling by invitationEpilepsy | Partial Seizures With or Without Secondary GeneralizationChina, Japan
-
ValexfarmCompletedEpilepsy | Complex Partial Seizures | Simple Partial Seizures | Partial Seizures With Secondary GeneralizationRussian Federation
-
University of North Carolina, Chapel HillFocused Ultrasound FoundationRecruitingPartial Seizures With Secondary GeneralizationUnited States
-
UCB Pharma GmbHCompletedFocal Epilepsy With and Without Secondary GeneralizationGermany, Austria
-
Whanin Pharmaceutical CompanyCompletedPartial-onset Seizures With or Without Secondary GeneralisationKorea, Republic of
-
UCB Biopharma S.P.R.L.Pharm Research Associates (UK) Ltd.CompletedEpilepsy With POS With or Without Secondary GeneralizationDenmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
-
Eisai Co., Ltd.CompletedPartial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic SeizuresJapan
Clinical Trials on SPM 927
-
UCB PharmaCompletedDiabetic NeuropathiesUnited States
-
UCB PharmaCompletedEpilepsies, PartialUnited States
-
UCB PharmaCompletedDiabetic NeuropathyUnited States
-
UCB PharmaCompleted
-
UCB PharmaCompleted
-
UCB PharmaCompleted
-
UCB PharmaSCHWARZ BIOSCIENCES GmbH - Part of UCB GroupCompletedPainful Diabetic NeuropathyGermany
-
UCB PharmaCompletedChronic Refractory Neuropathic PainGermany
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan